The Role of Inhibition of Apoptosis in Acute Leukemias and Myelodysplastic Syndrome
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Role of Inhibition of Apoptosis in Acute Leukemias and Myelodysplastic Syndrome
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-03-27
DOI
10.3389/fonc.2019.00192
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells
- (2018) Mohamed Rahmani et al. CANCER RESEARCH
- Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018
- (2018) Lorenzo Galluzzi et al. CELL DEATH AND DIFFERENTIATION
- Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents
- (2018) Yichao Wan et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies
- (2018) Andrew E Place et al. Future Oncology
- Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
- (2018) Courtney D DiNardo et al. LANCET ONCOLOGY
- Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
- (2018) Courtney D. DiNardo et al. BLOOD
- Combined venetoclax and alvocidib in acute myeloid leukemia
- (2017) James Bogenberger et al. Oncotarget
- Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia
- (2016) S. L. Khaw et al. BLOOD
- Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells
- (2016) X. Niu et al. CLINICAL CANCER RESEARCH
- Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models
- (2016) Christian Lehmann et al. Journal of Hematology & Oncology
- The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
- (2016) András Kotschy et al. NATURE
- Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
- (2016) M. Konopleva et al. Cancer Discovery
- MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors
- (2015) K L B Knorr et al. CELL DEATH AND DIFFERENTIATION
- The BCL-2 protein family, BH3-mimetics and cancer therapy
- (2015) A R D Delbridge et al. CELL DEATH AND DIFFERENTIATION
- Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients
- (2015) S Jilg et al. LEUKEMIA
- Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia
- (2015) Steven M Chan et al. NATURE MEDICINE
- Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)
- (2015) J D Leverson et al. Cell Death & Disease
- Maritoclax and dinaciclib inhibit MCL-1 activity and induce apoptosis in both a MCL-1-dependent and -independent manner
- (2015) Shankar Varadarajan et al. Oncotarget
- ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia
- (2014) S. Peirs et al. BLOOD
- Maritoclax induces apoptosis in acute myeloid leukemia cells with elevated Mcl-1 expression
- (2014) Kenichiro Doi et al. CANCER BIOLOGY & THERAPY
- Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach
- (2014) B. Higgins et al. CLINICAL CANCER RESEARCH
- A Phase II, Multicenter, Open-Label Study of Obatoclax Mesylate in Patients With Previously Untreated Myelodysplastic Syndromes With Anemia or Thrombocytopenia
- (2014) Martha L. Arellano et al. Clinical Lymphoma Myeloma & Leukemia
- BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies
- (2014) J M Bogenberger et al. LEUKEMIA
- Ex vivoactivity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies
- (2014) James M. Bogenberger et al. LEUKEMIA & LYMPHOMA
- Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199
- (2014) T. N. Chonghaile et al. Cancer Discovery
- Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
- (2013) Peter E. Czabotar et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
- (2013) R. Pan et al. Cancer Discovery
- Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells
- (2012) Twee Tsao et al. ANNALS OF HEMATOLOGY
- Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer
- (2012) C. M. Rudin et al. CLINICAL CANCER RESEARCH
- Discovery of Marinopyrrole A (Maritoclax) as a Selective Mcl-1 Antagonist that Overcomes ABT-737 Resistance by Binding to and Targeting Mcl-1 for Proteasomal Degradation
- (2012) Kenichiro Doi et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- BCL2/BCL-XL inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation
- (2011) M. Vogler et al. BLOOD
- Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets
- (2011) S. M. Schoenwaelder et al. BLOOD
- Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
- (2011) Leena Gandhi et al. JOURNAL OF CLINICAL ONCOLOGY
- MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex
- (2011) M Konopleva et al. LEUKEMIA
- Diminished Sensitivity of Chronic Lymphocytic Leukemia Cells to ABT-737 and ABT-263 Due to Albumin Binding in Blood
- (2010) M. Vogler et al. CLINICAL CANCER RESEARCH
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
- (2010) Wyndham H Wilson et al. LANCET ONCOLOGY
- Mechanisms of Antileukemic Activity of the Novel Bcl-2 Homology Domain-3 Mimetic GX15-070 (Obatoclax)
- (2008) M. Konopleva et al. CANCER RESEARCH
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
- A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies
- (2008) A. D. Schimmer et al. CLINICAL CANCER RESEARCH
- Discovery of an Orally Bioavailable Small Molecule Inhibitor of Prosurvival B-Cell Lymphoma 2 Proteins
- (2008) Cheol-Min Park et al. JOURNAL OF MEDICINAL CHEMISTRY
- Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program
- (2007) Richard Lock et al. PEDIATRIC BLOOD & CANCER
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started